Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

Restricted access

Interferon-α is possibly the most controversial adjuvant therapy for any solid tumor, and multiple trials involving varying doses, routes, schedules, and formulations of interferon-α have increased the confusion. Clinicians are left in a quandary, because high-dose interferon-α-2b (HDI) remains the only FDA-approved adjuvant therapy for high-risk melanoma. Of the three prospective randomized trials involving high-dose interferon-α-2b, all show a significant improvement in disease-free survival and two show a significant improvement in overall survival. Despite this strong evidence, data from studies involving alternate doses, concerns regarding cost and toxicity, and the promise of future therapies have led opponents of interferon to overlook these results. Based on the available clinical evidence, however, high-dose interferon should be offered as standard care for patients with high-risk, resected melanoma. Informed patients who have elected to forego interferon and patients with lower risk lesions can be offered participation in clinical trials with a no-treatment control arm.

Correspondence: Michael S. Sabel, MD, University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109. E-mail: msabel@umich.edu
  • 1

    BalchCMBuzaidACSoongS-J. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol2001;19:36353648.

    • Search Google Scholar
    • Export Citation
  • 2

    DicklerMNCoitDGMyersML. Adjuvant therapy of malignant melanoma. Surg Oncol Clin N Am1997; 6:793812.

  • 3

    PfefferLMDinarelloCAHerbermanRB. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res1998;58:24892499.

    • Search Google Scholar
    • Export Citation
  • 4

    FrankSJMeyersM. Interferon as adjuvant therapy for high risk melanoma. Melanoma Lett1995; 13:14.

  • 5

    LeghaSS. Current therapy for malignant melanoma. Semin Oncol1989;16:3444.

  • 6

    SteinerAWolfCHPehambergerH. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol1987;113:459465.

    • Search Google Scholar
    • Export Citation
  • 7

    EggermontAM. The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer2001;37:21472153.

  • 8

    PuntCJAEggermontAM. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies. Ann Oncol2001;12:16331666.

  • 9

    LensMBDawesM. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol2002;20:18181825.

    • Search Google Scholar
    • Export Citation
  • 10

    WheatleyKHancockBGoreM. Interferon-alpha as adjuvant therapy for melanoma: a meta-analysis of the randomized trials (Abstract). Proc Am Soc Clin Oncol2001;20:349a.

    • Search Google Scholar
    • Export Citation
  • 11

    KirkwoodJMManolaJIbrahimJ. Pooled analysis of four ECOG/Intergroup trials of high-dose interferon alpha-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma (Abstract). Proc Am Soc Clin Oncol2001; 20:350a.

    • Search Google Scholar
    • Export Citation
  • 12

    Thome'SDLoprinziCLHeldebrandtMP. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanoma. Mayo Clin Proc2002;77:913917.

    • Search Google Scholar
    • Export Citation
  • 13

    CascinelliNBufalinoRMorabitoAMackieR. Results of adjuvant interferon study in WHO melanoma programme (letter). Lancet1994;343:913914.

    • Search Google Scholar
    • Export Citation
  • 14

    CreaganETDaltonRJAhmannDL. Randomized, surgical adjuvant clinical trial of recombinant interferon alpha-2a in selected patients with malignant melanoma.J Clin Oncol1995;13:27762783.

    • Search Google Scholar
    • Export Citation
  • 15

    PehambergerHSoyerHPSteinerA. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol1998;16(4):14251429.

    • Search Google Scholar
    • Export Citation
  • 16

    GrobJJDrenoBde la SalmoniereP. Randomised trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. Lancet1998;351:19051910.

    • Search Google Scholar
    • Export Citation
  • 17

    HancockBWWheatleyKHarrisonG. Aim high: Adjuvant interferon in melanoma (high risk), a United Kingdom Cooordinating Committee on Cancer Research (UKCCCR) randomized study of observation versus adjuvant low-dose extended duration intereron alpha-2a in high risk resected malignant melanoma (Abstract). Proc Am Soc Clin Oncol2001;20:349a.

    • Search Google Scholar
    • Export Citation
  • 18

    KleebergURBrockerEBLejeuneFJ. Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (>3mm or regional lymph node metastasis (EORTC 18871). Eur J Cancer1999; 35 (Suppl 4):S82.

    • Search Google Scholar
    • Export Citation
  • 19

    CameronDACornbleetMCMackieRM. Adjuvant interferon alpha 2b in high risk melanoma—the Scottish study. Br J Cancer2001;84:11461149.

  • 20

    KirkwoodJMIbrahimJGSondakVK. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol2000;18:24442458.

    • Search Google Scholar
    • Export Citation
  • 21

    EggermontAMMGoreM. A critical appraisal of the role of interferon-α in the treatment of malignant melanoma. Principles and Practice of Biologic Therapy of Cancer Updates.Philadelphia: Lippincott Williams and Wilkins2002: p 3.

    • Search Google Scholar
    • Export Citation
  • 22

    ItriLMShermanMIPalleroniAV. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. J Interferon Res1989;9(suppl 1):S9S15.

    • Search Google Scholar
    • Export Citation
  • 23

    SpeigelRJJacobsSLTreuhaftMS. Anti-interferon antibodies to interferon-alpha 2b: Results of comparative assays and clinical perspective. J Interferon Res1989;9(suppl 1):S17S24.

    • Search Google Scholar
    • Export Citation
  • 24

    WussowPVJakschiesDFreundM. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Br J Haematol1991;78:210216.

    • Search Google Scholar
    • Export Citation
  • 25

    KokoschkaEMTrautingerFKnoblerRM. Long-term adjuvant therapy of high risk malignant melanoma with interferon a2b. J Invest Dermatol1990;95:S193197.

    • Search Google Scholar
    • Export Citation
  • 26

    CascinelliN. Evaluation of efficacy of adjuvant rIFN-α 2a in melanoma patients with regional node metastases (Abstract). Proc Am Soc Clin Oncol1994;14:410.

    • Search Google Scholar
    • Export Citation
  • 27

    RuscianiLPetragliaSAlottoM. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer1997;79:23542360.

    • Search Google Scholar
    • Export Citation
  • 28

    KirkwoodJMStrawdermanMHErnstoffMS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol1996;14:717.

    • Search Google Scholar
    • Export Citation
  • 29

    KirkwoodJMIbrahimJGSosmanJA. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol2001;19:23702380.

    • Search Google Scholar
    • Export Citation
  • 30

    LivingstonPOWongGYAdluriS. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol1994;12:10361044.

    • Search Google Scholar
    • Export Citation
  • 31

    RodenhuisSBontenbalMBeexLVAM. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med2003;349:716.

    • Search Google Scholar
    • Export Citation
  • 32

    TallmanMSGrayRRobertNJ. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med2003;349:1726.

    • Search Google Scholar
    • Export Citation
  • 33

    ElfenbeinGJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med2003;349:8082.

  • 34

    KilbridgeKLWeeksJCSoberAJ. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol2001;19:812823.

  • 35

    SpiraAIEttingerDS. The use of chemotherapy in soft-tissue sarcomas. Oncologist2002;7:348359.

  • 36

    DavidsonNE. Ongoing US cooperative groups trials using taxanes in the adjuvant setting. Clin Breast Cancer2002;3(Suppl 2):S53S58.

  • 37

    SaltzLBMinskyB. Adjuvant therapy of cancers of the colon and rectum. Surg Clin North Am2002;82:10351058.

  • 38

    ColeBFGelberRDKirkwoodJM. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol1996;14:26662673.

    • Search Google Scholar
    • Export Citation
  • 39

    HillnerBE. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. Eur J Cancer1998;34(suppl 3):S18S21.

    • Search Google Scholar
    • Export Citation
  • 40

    HillnerBEKirkwoodJMAtkinsMB. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol1997;15:23512358.

    • Search Google Scholar
    • Export Citation
  • 41

    Gonzalez-LarribaJLSerranoSAlvarez-MonM. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer2000;36:23442352.

    • Search Google Scholar
    • Export Citation
  • 42

    CookJZitelliJA. Treating patients with melanoma with interferon (letter). Arch Dermatol1997;133:387.

  • 43

    Russell-JonesR. Interferon-α therapy for melanoma. Clin Exp Dermatol2000;25:16.

  • 44

    MortonDLHsuehECEssnerR. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg2002;236:438449.

    • Search Google Scholar
    • Export Citation
  • 45

    MortonDLBarthA. Vaccine therapy for malignant melanoma. CA Cancer J Clin1996;46:225244.

  • 46

    HsuehECEssnerRFoshagLJ. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol2002;9:486492.

    • Search Google Scholar
    • Export Citation
  • 47

    SondakVKLiuPYTuthillRJ. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol2002;20:20582066.

    • Search Google Scholar
    • Export Citation
  • 48

    SosmanJAUngerJMLiuPY. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol2002;20:20672075.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 44 44 8
PDF Downloads 3 3 0
EPUB Downloads 0 0 0